Netarsudil for Glaucoma and Ocular Hypertension

This trial examines the effectiveness of netarsudil (Rhopressa) for individuals with ocular hypertension (high eye pressure) or open-angle glaucoma. Researchers aim to determine if this treatment affects the trabecular meshwork, which helps drain fluid and maintain eye pressure. Participants will receive either netarsudil (an ophthalmic solution) or a placebo (artificial tears) for about two weeks. The trial is suitable for those diagnosed with ocular hypertension or open-angle glaucoma, who have had an eye exam in the past year, and do not have certain eye conditions that could interfere with the study. As a Phase 4 trial, this research involves an FDA-approved treatment and seeks to understand its benefits for more patients.

The trial information does not specify if you need to stop your current medications. However, it mentions a 'washout' period, which means you might need to stop certain eye medications before starting the trial. It's best to discuss this with the trial team.

Research has shown that netarsudil, also known as Rhopressa, is generally safe for use. Studies have demonstrated its effectiveness in lowering eye pressure in patients with glaucoma and high eye pressure. Importantly, the FDA has already approved netarsudil for these conditions, indicating a strong safety record.

Netarsudil (Rhopressa) is unique because it targets the trabecular meshwork, a key drainage pathway in the eye, to reduce intraocular pressure in glaucoma and ocular hypertension patients. Unlike most treatments that mainly increase fluid outflow through other pathways or decrease fluid production, Netarsudil works by inhibiting Rho kinase. This mechanism not only enhances fluid drainage but also potentially offers neuroprotective benefits, which could be a game-changer in preventing vision loss. Researchers are excited because this dual-action approach addresses both pressure reduction and nerve protection, offering a comprehensive treatment option.

Research has shown that netarsudil (Rhopressa), which participants in this trial may receive, effectively lowers eye pressure in individuals with open-angle glaucoma or high eye pressure. Studies have found it can reduce eye pressure by 1-5 mmHg, which is important for managing these conditions. One study demonstrated that netarsudil performed as well as timolol, a common glaucoma treatment taken twice daily. For patients with lower starting eye pressure, 69% achieved treatment success, indicating a significant reduction. Overall, netarsudil effectively lowers eye pressure, crucial for preventing optic nerve damage and protecting vision.¹²³⁵⁶